Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
{{output}}
Pralatrexate, a 10-deazaaminopterin derivative, is being developed by Allos Therapeutics Inc for the potential treatment of malignancies. The folate analog inhibits dihydrofolate reductase and was developed to overcome the limitations of the folate analog meth... ...
